Suzhou Transcenta partnered with California’s Agilent Technologies to develop a companion diagnostic for Osemitamab, a Claudin18.2 mAb. Transcenta has developed a mouse anti-CLDN18.2 monoclonal antibody, clone 14G11, that specifically binds to CLDN18.2 but not CLDN18.1. The antibody, generated against a linear epitope located on the extracellular domain of loop 1, has a binding site that overlaps the binding site of Osemitamab. Agilent is developing an immunohistochemistry assay that detects CLDN18.2 protein. Transcenta will use the assay to select patients for the Phase III trial of Osemitamab in gastric and gastroesophageal junction adenocarcinoma. More details....

Stock Symbol: (HK: 06628)

Share this with colleagues:  

Beijing’s YS Biopharma reported positive results from the ongoing Phase III clinical trial of its next-gen PIKA Rabies Vaccine. The company said interim results show that the vaccine has met its primary endpoints with potential to offer best-in-class accelerated protection and meet the WHO's goal of a one-week rabies vaccine regimen that would replace the usual three- or four-week regimens. YS Biopharma is a China-US biopharma that develops vaccines and therapeutic biologics for infectious diseases and cancer. More details....

Stock Symbol: (NSDQ: YS)

Share this with colleagues:  

Shanghai Abbisko Therapeutics has completed patient enrollment for a pivotal global Phase III trial of pimicotinib in patients with tenosynovial giant cell tumor (TGCT). Pimicotinib is a novel, orally available small molecule inhibitor of CSF-1R. TGCT is a benign tumor that can cause painful joint swelling and stiffness. In late 2023, Abbisko sold greater China commercial rights to the drug for TGCT to Germany’s Merck in a $605 million agreement, including $70 million upfront. Merck has an option to add global rights to the candidate. The trial enrolled 94 patients at sites in China, the US and EU. More details....

Share this with colleagues:  

Sichuan Kelun-Biotech and Merck reported preliminary Phase I/II data showing their partnered TROP2-directed ADC produced a promising disease control rate and potential to extend survival in heavily pretreated patients with gastric or gastroesophageal junction cancer. SKB264 achieved a 22% objective response rate in 41 patients while disease control rate was 80.5%, with a median duration of response of 7.5 months. Known as MSD outside of the US, Merck acquired global rights (ex-China) to SKB264 in a $1.4 billion agreement, one of three ADC partnerships (worth up to $12 billion) the two companies formed in 2022. More details....

Stock Symbol: (NYSE: MRK)

Share this with colleagues:  

Shenzhen Kexing Biopharm has started a Phase III clinical trial of an inhaled Interferon aIb therapy for respiratory syncytial virus-associated lower respiratory infections (pneumonia, bronchiolitis) in children. The nebulized product delivers active ingredients to the lesion site, an efficient and rapid means of administration, but nebulized products are not generally approved for use in children. In earlier trials, the therapy showed high levels of the drug in the lesion site, but low plasma concentration and excellent safety, according to Kexing. More details....

Stock Symbol: (SHA: 688136)

Share this with colleagues: